255 related articles for article (PubMed ID: 31768027)
1. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.
Imai M; Yamashita M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Kiso M; Murakami J; Yasuhara A; Takada K; Ito M; Nakajima N; Takahashi K; Lopes TJS; Dutta J; Khan Z; Kriti D; van Bakel H; Tokita A; Hagiwara H; Izumida N; Kuroki H; Nishino T; Wada N; Koga M; Adachi E; Jubishi D; Hasegawa H; Kawaoka Y
Nat Microbiol; 2020 Jan; 5(1):27-33. PubMed ID: 31768027
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
3. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
[TBL] [Abstract][Full Text] [Related]
4. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.
Takashita E; Ichikawa M; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Sugawara H; Sato A; Akimoto M; Mitamura K; Abe T; Yamazaki M; Watanabe S; Hasegawa H; Odagiri T
Emerg Infect Dis; 2019 Nov; 25(11):2108-2111. PubMed ID: 31436527
[TBL] [Abstract][Full Text] [Related]
5. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
Lee LYY; Zhou J; Frise R; Goldhill DH; Koszalka P; Mifsud EJ; Baba K; Noda T; Ando Y; Sato K; Yuki AI; Shishido T; Uehara T; Wildum S; Zwanziger E; Collinson N; Kuhlbusch K; Clinch B; Hurt AC; Barclay WS
PLoS Pathog; 2020 Apr; 16(4):e1008395. PubMed ID: 32294137
[TBL] [Abstract][Full Text] [Related]
6. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
7. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
[TBL] [Abstract][Full Text] [Related]
8. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
9. Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.
Chesnokov A; Patel MC; Mishin VP; De La Cruz JA; Lollis L; Nguyen HT; Dugan V; Wentworth DE; Gubareva LV
J Infect Dis; 2020 Jan; 221(3):367-371. PubMed ID: 31541547
[TBL] [Abstract][Full Text] [Related]
10. Baloxavir heralds a new era in influenza virus biology.
Kikuchi T; Watanabe A
Respir Investig; 2019 Jan; 57(1):1-2. PubMed ID: 30396860
[TBL] [Abstract][Full Text] [Related]
11. Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
Jones JC; Rovito SW; Penaflor MK; Webby RJ; Govorkova EA
Antiviral Res; 2022 Aug; 204():105369. PubMed ID: 35738347
[TBL] [Abstract][Full Text] [Related]
12. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.
Takashita E; Kawakami C; Ogawa R; Morita H; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Ota A; Togashi H; Saito A; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T
Euro Surveill; 2019 Mar; 24(12):. PubMed ID: 30914078
[TBL] [Abstract][Full Text] [Related]
13. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
Gubareva LV; Mishin VP; Patel MC; Chesnokov A; Nguyen HT; De La Cruz J; Spencer S; Campbell AP; Sinner M; Reid H; Garten R; Katz JM; Fry AM; Barnes J; Wentworth DE
Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670144
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
Lee LY; Zhou J; Koszalka P; Frise R; Farrukee R; Baba K; Miah S; Shishido T; Galiano M; Hashimoto T; Omoto S; Uehara T; Mifsud EJ; Collinson N; Kuhlbusch K; Clinch B; Wildum S; Barclay WS; Hurt AC
PLoS Pathog; 2021 May; 17(5):e1009527. PubMed ID: 33956888
[TBL] [Abstract][Full Text] [Related]
15. Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019-2020 Influenza Season.
Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Fujisaki S; Hashimoto K; Hosoya M
J Infect Dis; 2021 Nov; 224(10):1735-1741. PubMed ID: 33837427
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
Mishin VP; Patel MC; Chesnokov A; De La Cruz J; Nguyen HT; Lollis L; Hodges E; Jang Y; Barnes J; Uyeki T; Davis CT; Wentworth DE; Gubareva LV
Emerg Infect Dis; 2019 Oct; 25(10):1969-1972. PubMed ID: 31287050
[TBL] [Abstract][Full Text] [Related]
17. Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse.
Nemoto M; Tamura N; Bannai H; Tsujimura K; Kokado H; Ohta M; Yamanaka T
J Gen Virol; 2019 Nov; 100(11):1471-1477. PubMed ID: 31526451
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Noshi T; Kitano M; Taniguchi K; Yamamoto A; Omoto S; Baba K; Hashimoto T; Ishida K; Kushima Y; Hattori K; Kawai M; Yoshida R; Kobayashi M; Yoshinaga T; Sato A; Okamatsu M; Sakoda Y; Kida H; Shishido T; Naito A
Antiviral Res; 2018 Dec; 160():109-117. PubMed ID: 30316915
[TBL] [Abstract][Full Text] [Related]
19. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
Takashita E; Kawakami C; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T;
Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670142
[TBL] [Abstract][Full Text] [Related]
20. Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil.
Yoshino R; Yasuo N; Sekijima M
Sci Rep; 2019 Nov; 9(1):17464. PubMed ID: 31767949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
